What is "ozanezumab"

Ozanezumab is a monoclonal antibody designed for the treatment of ALS and multiple sclerosis.

Ozanezumab targets a protein called Neurite Outgrowth Inhibitor (NOGO-A) or Reticulon 4. NOGO-A is a protein that in humans is encoded by the RTN4 gene that has been identified as an inhibitor of neurite outgrowth specific to the central nervous system. NOGO-A is found at higher than normal levels in persons with MND.

This drug was developed by GlaxoSmithKline under the identifier GSK 1223249.